EMA Addresses Early, Asymptomatic Alzheimer’s In ‘Hugely Important’ Clinical Study Guidance

The European Medicines Agency expects its revised guidance to facilitate the development of medicines to prevent and treat Alzheimer’s disease.

Alzheimer's
Revised EMA guidance will help companies developing Alzheimer's drug • Source: Shutterstock

More from Clinical Trials

More from R&D